Neumora Therapeutics financials
$0.6776−2.05%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$42.2M | -$52.9M | -$58.5M | -$57.7M | -$54.0M | -$70.9M | -$62.9M | -$76.6M | -$63.8M | -$60.1M | -$114.0M | -$56.9M |
| Net income | -$43.1M | -$53.5M | -$59.5M | -$56.8M | -$52.7M | -$68.1M | -$58.8M | -$72.5M | -$58.7M | -$53.7M | -$108.7M | -$53.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.23 | $-0.30 | $-0.35 | $-0.35 | $-0.33 | $-0.42 | $-0.37 | $-0.45 | $-0.37 | $-0.34 | $-0.71 | $-1.14 |
| EBITDA | -$42.2M | -$52.9M | -$58.5M | -$57.7M | -$54.0M | -$70.8M | -$62.8M | -$76.5M | -$62.5M | -$61.1M | -$114.5M | -$57.7M |
| Operating cash flow | -$39.5M | -$46.4M | -$48.0M | -$46.6M | -$52.4M | -$59.4M | -$50.3M | -$33.5M | -$55.4M | -$43.7M | -$56.0M | -$47.8M |
| Free cash flow | -$39.5M | -$46.4M | -$48.0M | -$46.6M | -$52.4M | -$59.4M | -$50.3M | -$33.5M | -$55.4M | -$43.7M | -$56.1M | -$47.8M |
| Diluted shares | 185.2M | 179.9M | 168.6M | 161.8M | 161.7M | 161.5M | 161.0M | 159.6M | 159.0M | 157.9M | 154.0M | 46.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $116.8M | $147.1M | $182.5M | $129.1M | $124.5M | $126.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $42.5M | $93.1M | $122.5M |
| Total debt | $52.9M | $53.0M | $54.5M | $19.6M | $19.5M | $0.00 |
| Total assets | $125.2M | $153.9M | $191.0M | $177.8M | $223.8M | $256.7M |
| Total liabilities | $80.7M | $83.2M | $87.2M | $45.7M | $40.9M | $28.4M |
| Shareholders' equity | $44.5M | $70.7M | $103.9M | $132.2M | $182.9M | $228.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology